Latest Administration News

Lodestar Minerals has defined its first Exploration Target at the Neds Creek Gold Project in Western Australia, estimating up to 300,000 ounces of gold within an open-pit framework. The company plans a significant drilling campaign in early 2026 to validate and potentially upgrade this target to a JORC-compliant Mineral Resource.

Actinogen Medical has finalized enrollment and begun treatment of all 246 participants in its XanaMIA Phase 2b/3 Alzheimer’s trial, with topline results expected in November 2026. The oral drug Xanamem targets brain cortisol to potentially slow disease progression.

Buru Energy is actively pursuing funding for its 2026 drilling campaign to validate resources at the Rafael Gas Project, aiming for a Final Investment Decision in the second half of 2026 and first cashflow by 2028.

Telix Pharmaceuticals confirms completion of Part 1 enrolment in its ProstACT Phase 3 trial for prostate cancer, with safety data supporting progression to Part 2 and regulatory approvals secured across multiple countries.

Epsilon Healthcare reported a 19% revenue increase to $3.4 million for the half year ended June 2025, driven by new client wins and its pharmacy segment launch. However, net losses widened 44% to $2.07 million, reflecting administration and financing costs during its recovery phase.

Alara Resources and partners have completed their maiden drilling program at Oman’s Block 8, revealing encouraging copper and zinc mineralisation consistent with Volcanogenic Massive Sulphide deposits. The results validate the geological model and set the stage for further exploration.

AWAG has accelerated its growth trajectory by doubling its authorised representatives and increasing funds under management to $3.6 billion through strategic investments in Avalon Financial Services and SWR Chartered Accountants.

Entropy Neurodynamics has successfully completed dosing the first patient in its TRP-8803 clinical trial for Binge Eating Disorder, marking a key milestone with controlled psychedelic infusion and safety clearance. Top-line results are expected in early 2026.

Sequoia Financial Group reports a 15% rise in EBITDA year-to-date November 2025 despite legacy claim settlements and expected impairments, while its APAC expansion gains momentum.

Lake Resources has disclosed an inadvertent breach of ASX Listing Rule 7.1 related to the timing of share issuance under an agreement with Acuity Capital. The company is taking steps to strengthen governance and prevent future errors.

Radiopharm Theranostics reports promising interim Phase 2b results for RAD 101, achieving 92% concordance with MRI in detecting brain metastases, paving the way for a pivotal study in 2026.

AusQuest and South32 have extended their Strategic Alliance Agreement for two more years, securing continued funding and collaboration on Australian copper and zinc projects. South32 will fund exploration to advance projects to drill-ready status and can earn up to 80% interest through staged investments.